Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABRILADA vs AVSOLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.
Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.
Rheumatoid arthritis,Juvenile idiopathic arthritis,Psoriatic arthritis,Ankylosing spondylitis,Crohn's disease,Ulcerative colitis,Plaque psoriasis,Hidradenitis suppurativa,Uveitis
Crohn's disease (moderate to severe, fistulizing),Pediatric Crohn's disease (moderate to severe),Ulcerative colitis (moderate to severe),Pediatric ulcerative colitis (moderate to severe),Rheumatoid arthritis (in combination with methotrexate),Ankylosing spondylitis,Psoriatic arthritis,Plaque psoriasis (chronic severe)
80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
Terminal elimination half-life approximately 10–14 days in adults, supporting every-other-week dosing; may be shorter in pediatric patients.
Terminal elimination half-life is approximately 14–18 days (range 10–39 days) in adults. Prolonged half-life supports dosing every 8 weeks; it is influenced by inflammation and disease severity.
Adalimumab is a monoclonal antibody that is metabolized via catabolism into peptides and amino acids. CYP450 enzymes are not involved. No active metabolites.
Infliximab is a monoclonal antibody; metabolism is via catabolism into peptides and amino acids through general protein degradation pathways (reticuloendothelial system). No involvement of CYP450 enzymes.
Primarily degraded into amino acids and recycled or excreted in urine (less than 1% unchanged); no significant biliary/fecal elimination.
Primarily cleared by the reticuloendothelial system via proteolytic degradation. Minimal renal excretion (less than 1% unchanged) and no significant biliary or fecal elimination.
Approximately 95% bound to serum proteins, primarily alpha-1-acid glycoprotein and albumin.
Predominantly bound to soluble TNF-alpha; no specific plasma protein binding (e.g., albumin) is reported; the complex is cleared, so free drug binding is low.
Approximately 4.7–6.0 L/kg, indicating extensive distribution into tissues consistent with a monoclonal antibody.
Volume of distribution is approximately 0.04–0.06 L/kg, indicating limited tissue distribution primarily within the vascular space.
Subcutaneous: approximately 64% (range 50–80%) absolute bioavailability relative to intravenous administration.
Bioavailability is 100% after intravenous infusion; no other routes are clinically relevant.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use with caution.
No dose adjustment required for renal impairment.
No formal studies in hepatic impairment. Use with caution in moderate to severe impairment (Child-Pugh B or C) due to limited data.
No formal studies; use caution in hepatic impairment.
Approved for pediatric plaque psoriasis (≥12 years): 80 mg subcutaneously every other week. For pediatric psoriatic arthritis (≥12 years): 80 mg subcutaneously every other week. For pediatric hidradenitis suppurativa (≥12 years, ≥60 kg): 160 mg on day 1, then 80 mg every other week. Pediatric Crohn's disease (≥6 years, ≥40 kg): 160 mg on day 1, then 80 mg on day 15, then 80 mg every other week; for <40 kg: 80 mg on day 1, then 40 mg on day 15, then 40 mg every other week.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; approved for ages 6 years and older.
No specific dose adjustment required; but monitor for infections in patients ≥65 years due to increased risk.
No specific dose adjustment; monitor for infections and adverse effects.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. SERIOUS INFECTIONS: Patients treated with adalimumab are at increased risk for serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue adalimumab if a serious infection develops. MALIGNANCY: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Increased risk of serious infections (including tuberculosis, bacterial sepsis, invasive fungal infections) leading to hospitalization or death; increased risk of lymphoma and other malignancies, including fatal hepatosplenic T-cell lymphoma in adolescents and young adults with inflammatory bowel disease.
Serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens,Hepatitis B virus reactivation,Hypersensitivity reactions including anaphylaxis and angioneurotic edema,Neurologic events including new onset or exacerbation of demyelinating disorders,Hematologic events including pancytopenia and aplastic anemia,Congestive heart failure,Lupus-like syndrome,Malignancies including lymphoma, leukemia, and other malignancies
Risk of serious infections (screen for latent TB and treat before initiation, monitor for active infections),Hypersensitivity reactions (including anaphylaxis, serum sickness),Hepatotoxicity (including hepatic failure, acute liver injury),Reactivation of hepatitis B virus,Hematologic toxicity (pancytopenia, leukopenia),Neurologic events (demyelinating disorders, seizure, optic neuritis),Heart failure exacerbation,Lupus-like syndrome,Immunogenicity (development of anti-drug antibodies leading to infusion reactions and loss of response),Malignancy (especially lymphoma, leukemia, melanoma, and Merkel cell carcinoma)
Known hypersensitivity to adalimumab or any inactive component of the product,Active serious infections including sepsis, tuberculosis, and opportunistic infections
History of severe hypersensitivity to infliximab or any murine proteins,Moderate to severe heart failure (NYHA class III/IV),Active serious infections (including sepsis, abscesses, tuberculosis, opportunistic infections),Concurrent use with abatacept or anakinra (increased risk of infection)
No significant food interactions. Grapefruit and other CYP450 modulators do not affect adalimumab. Take without regard to meals.
No known food interactions. AVSOLA is administered intravenously, and its absorption is not affected by oral intake. However, patients should maintain a balanced diet to support immune function.
Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates exposed in utero. First trimester: Minimal known risk. Second/third trimester: May cross placenta; theoretical risk of immunosuppression.
AVSOLA (infliximab-axxq) is a monoclonal antibody. Ig G crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated with low risk of major malformations. Second and third trimester exposure may increase risk of fetal immunosuppression, including neonatal lymphopenia, and vaccination risks. Avascular necrosis and congenital anomalies have been reported post-marketing but causal relationship not established. Avoid live vaccines in infants exposed in utero for 6 months.
Excreted in human milk in low concentrations; M/P ratio not well defined. Considered compatible with breastfeeding, but monitor infant for infection risks.
Infliximab is excreted in breast milk in small amounts; M/P ratio (milk to plasma ratio) is approximately 0.001-0.002. Oral bioavailability in infants is low due to gastrointestinal degradation. Limited data show no adverse effects in breastfed infants. However, consider maternal dosage, infant age, and risk of immunosuppression. Benefit of breastfeeding likely outweighs minimal risk.
No dose adjustment routinely required; pregnancy may increase clearance, but no established guidelines for dose modification.
Pharmacokinetics of infliximab may be altered due to increased plasma volume, renal clearance, and third-spacing during pregnancy. However, no specific dose adjustment guidelines are established. Most studies recommend maintaining standard dosing throughout pregnancy to ensure therapeutic levels. Monitor clinical response and consider therapeutic drug monitoring if needed. Postpartum, no dose adjustment required, but reassess for disease flare.
ABRILADA (adalimumab) is a TNF-alpha inhibitor. Monitor for latent TB reactivation with PPD or IGRA before initiation. Injection site reactions are common; rotate sites and apply cold compresses. Avoid live vaccines during therapy. Assess for new-onset or worsening heart failure, demyelinating disorders, and cytopenias. Increased risk of serious infections; screen for HBV, HCV, and fungal infections. Consider temporarily holding therapy for major surgical procedures.
AVSOLA (infliximab-axxq) is a biosimilar to Remicade. Pre-medicate with antihistamines and acetaminophen to reduce infusion reactions. Screen for latent TB (PPD or IGRA) and HBV before initiation. Do not administer live vaccines during therapy. Monitor for signs of infection, including opportunistic infections like histoplasmosis. Discontinue if symptoms of lupus-like syndrome or severe hepatotoxicity occur. Infusion reactions may occur up to 2 hours post-infusion; have emergency equipment available.
Inspect injection site for redness, swelling, or itching; apply cold compress if needed.,Report signs of infection: fever, cough, painful urination, or skin wounds.,Avoid live vaccines (e.g., MMR, shingles, nasal flu) during treatment.,Review all current medications, including OTC and herbal supplements.,Notify healthcare provider before any planned surgery.,Use reliable contraception if of childbearing potential; continue 5 months after stopping.,Report new or worsening symptoms: shortness of breath, chest pain, numbness, vision changes.,Store ABRILADA in the refrigerator (36°F-46°F); do not freeze or shake.
AVSOLA is given as an IV infusion over at least 2 hours; you will be monitored during and after infusion.,Report any signs of allergic reaction (hives, difficulty breathing, swelling) immediately.,Seek medical help if you develop fever, chills, persistent cough, or skin changes.,Do not receive live vaccines while on AVSOLA; update vaccinations before starting.,Avoid becoming pregnant during treatment; use effective contraception.,Notify your doctor of any new or worsening symptoms, including chest pain or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABRILADA vs AVSOLA, answered by our medical review team.
ABRILADA is a TNF-Alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including changes in adhesion molecules, chemotaxis, and apoptosis.. AVSOLA is a TNF-Alpha Inhibitor that works by Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABRILADA and AVSOLA depend on the specific clinical indication. These are both TNF-Alpha Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABRILADA is: 80 mg subcutaneously every other week. For patients weighing ≥100 kg, 80 mg every week.. The standard adult dose of AVSOLA is: 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABRILADA and AVSOLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABRILADA is classified as Category C. Abrilada (adalimumab-adbm) is a TNF-alpha inhibitor. Limited human data; animal studies show no evidence of teratogenicity. Potential risk of increased infection in neonates expose. AVSOLA is classified as Category C. AVSOLA (infliximab-axxq) is a monoclonal antibody. IgG crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.